TOXICOLOGICAL PROFILE FOR
JET FUELS JP-4 AND JP-7

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

June 1995
DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.
UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333
FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and the Environmental Protection Agency (EPA) and in support of Department of Defense information needs. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance’s toxicologic properties. Other pertinent literature is also presented, but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance’s relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, when known, significant health effects. The adequacy of information to determine a substance’s health effects is described in a health effects summary. Data needs that are significant to protect public health will be identified by ATSDR and the EPA. The focus of the profiles is on health and toxicologic information; therefore, we have included this information in the beginning of the document.

Each profile must include the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects.

(C) When appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that might present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). Section 211 of SARA also amended Title 10 of the U. S. Code, creating the Defense Environmental Restoration Program. Section 2704(a) of Title 10 of the U. S. Code directs the Secretary of Defense to notify the Secretary of Health and Human Services of not less than 25 of the most commonly found unregulated hazardous substances at defense facilities.

Section 2704(b) of Title 10 of the U. S. Code directs the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare a toxicological profile for each substance on the list provided by the Secretary of Defense under subsection (b).
Foreword

This profile reflects our assessment of all relevant toxicologic testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

David Satcher, M.D., Ph.D.
Administrator
Agency for Toxic Substances and Disease Registry
CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Obaid Faroon, Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

Diane Mandell, Ph.D.
Clement International Corp., Fairfax, VA

Hernan Navarro, Ph.D.
Research Triangle Institute, Research Triangle Park, NC

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:


2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.

3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.

4. Quality Assurance Review. The Quality Assurance Branch assures that consistency across profiles is maintained, identifies any significant problems in format or content, and establishes that Guidance has been followed.
PEER REVIEW

A peer review panel was assembled for JP-4 and JP-7. The panel consisted of the following members:

1. Dr. William Nick Norton, Professor, Biology Department, Southeastern Louisiana University, Hammond, Louisiana;

2. Dr. Laurence Martin Holland, Private Consultant, 215 Rio Bravo, Los Alamos, New Mexico;

3. Dr. Arthur Gregory, Private Consultant, Techto Enterprises, Sterling, Virginia;

4. Dr. Tim Borges, Technical Information Analyst, Oak Ridge National Laboratory, Oak Ridge, Tennessee; and

5. Dr. Bruce Jacobs, Environmental Health Engineering Services Manager, General Physics Corporation, Edgewood, Maryland.

These experts collectively have knowledge of JP-4’s and JP-7’s physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers’ comments and determined which comments will be included in the profile. A listing of the peer reviewers’ comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile’s final content. The responsibility for the content of this profile lies with the ATSDR.
## CONTENTS

**FOREWORD** ........................................................................................................... v

**CONTRIBUTORS** ................................................................................................... vii

**PEER REVIEW** ....................................................................................................... ix

**LIST OF FIGURES** ................................................................................................. xv

**LIST OF TABLES** .................................................................................................... xvii

1. **PUBLIC HEALTH STATEMENT** ......................................................................... 1
   1.1 WHAT ARE JET FUELS JP-4 AND JP-7? .............................................................. 2
   1.2 WHAT HAPPENS TO JET FUELS JP-4 AND JP-7 WHEN THEY ENTER THE ENVIRONMENT? .......................................................... 2
   1.3 HOW MIGHT I BE EXPOSED TO JET FUELS JP-4 AND JP-7? ......................... 3
   1.4 HOW CAN JET FUELS JP-4 AND JP-7 ENTER AND LEAVE MY BODY? ............ 4
   1.5 HOW CAN JET FUELS JP-4 AND JP-7 AFFECT MY HEALTH? ......................... 4
   1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO JET FUELS JP-4 AND JP-7? .............................. 5
   1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? ................................. 5
   1.8 WHERE CAN I GET MORE INFORMATION? ...................................................... 6

2. **HEALTH EFFECTS** .............................................................................................. 7
   2.1 INTRODUCTION ................................................................................................. 7
   2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .................... 7
     2.2.1 Inhalation Exposure ....................................................................................... 8
     2.2.1.1 Death ....................................................................................................... 8
     2.2.1.2 Systemic Effects ..................................................................................... 9
     2.2.1.3 Immunological and Lymphoreticular Effects ........................................... 25
     2.2.1.4 Neurological Effects .............................................................................. 25
     2.2.1.5 Reproductive Effects ............................................................................ 26
     2.2.1.6 Developmental Effects .......................................................................... 26
     2.2.1.7 Genotoxic Effects ................................................................................ 27
     2.2.1.8 Cancer .................................................................................................. 27
     2.2.2 Oral Exposure .............................................................................................. 28
     2.2.2.1 Death .................................................................................................... 28
     2.2.2.2 Systemic Effects .................................................................................... 28
     2.2.2.3 Immunological and Lymphoreticular Effects ......................................... 28
     2.2.2.4 Neurological Effects .............................................................................. 28
     2.2.2.5 Reproductive Effects ............................................................................ 28
     2.2.2.6 Developmental Effects .......................................................................... 28
     2.2.2.7 Genotoxic Effects ................................................................................ 29
     2.2.2.8 Cancer .................................................................................................. 30
2.2.3 Dermal Exposure ........................................... 30
  2.2.3.1 Death ................................................. 30
  2.2.3.2 Systemic Effects ..................................... 31
  2.2.3.3 Immunological and Lymphoreticular Effects .......... 35
  2.2.3.4 Neurological Effects .................................. 35
  2.2.3.5 Reproductive Effects .................................. 35
  2.2.3.6 Developmental Effects .................................. 35
  2.2.3.7 Genotoxic Effects ..................................... 36
  2.2.3.8 Cancer ................................................ 36
2.3 TOXICOLOGINETICS ........................................... 36
  2.3.1 Absorption ............................................... 36
    2.3.1.1 Inhalation Exposure ................................ 36
    2.3.1.2 Oral Exposure ....................................... 37
    2.3.1.3 Dermal Exposure .................................... 37
  2.3.2 Distribution .............................................. 37
  2.3.3 Metabolism ................................................. 37
  2.3.4 Excretion ................................................ 37
  2.3.5 Mechanisms of Action .................................... 38
2.4 RELEVANCE TO PUBLIC HEALTH ................................ 38
2.5 BIOMARKERS OF EXPOSURE AND EFFECT .......................... 49
  2.5.1 Biomarkers Used to Identify or Quantify Exposure to Jet Fuels JP-4 and JP-7 ........................................ 50
  2.5.2 Biomarkers Used to Characterize Effects Caused by Jet Fuels JP-4 and JP-7 ........................................ 51
2.6 INTERACTIONS WITH OTHER CHEMICALS .......................... 51
2.7 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ...................... 51
2.8 METHODS FOR REDUCING TOXIC EFFECTS .......................... 52
  2.8.1 Reducing Peak Absorption Following Exposure ............ 52
  2.8.2 Reducing Body Burden .................................... 52
  2.8.3 Interfering with the Mechanism of Action for Toxic Effects ........................................ 52
2.9 ADEQUACY OF THE DATABASE .................................. 53
  2.9.1 Existing Information on Health Effects of Jet Fuels JP-4 and JP-7 ........................................ 53
  2.9.2 Identification of Data Needs ................................ 56
  2.9.3 Ongoing Studies .......................................... 61

3. CHEMICAL AND PHYSICAL INFORMATION ............................ 63
  3.1 CHEMICAL IDENTITY .......................................... 63
  3.2 PHYSICAL AND CHEMICAL PROPERTIES .......................... 64

4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .................. 75
  4.1 PRODUCTION ................................................. 75
  4.2 IMPORT/EXPORT .............................................. 76
  4.3 USE ...................................................... 76
  4.4 DISPOSAL .................................................. 77
LIST OF FIGURES

2-1 Levels of Significant Exposure to Jet Fuels - Inhalation ........................................ 17
2-2 Existing Information on Health Effects of JP-4 ......................................................... 54
2-3 Existing Information on Health Effects of JP-7 ......................................................... 55
5-1 Frequency of NPL Sites with Jet Fuel (JP-4) Contamination ....................................... 81
### LIST OF TABLES

2-1  Levels of Significant Exposure to Jet Fuels - Inhalation ............................................. 10

2-2  Levels of Significant Exposure to Jet Fuels - Dermal .................................................. 32

2-3  Genotoxicity of JP-4 *In Vivo* ................................................................. 47

2-4  Genotoxicity of JP-4 *In Vitro* ............................................................................... 48

3-1  Chemical Identity of JP-4 ...................................................................................... 65

3-2  Chemical Identity of JP-7 ...................................................................................... 66

3-3  Physical and Chemical Properties of JP-4 .............................................................. 67

3-4  Physical and Chemical Properties of JP-7 .............................................................. 68

3-5  Composition of Shale-derived and Petroleum-derived JP-4 ...................................... 69

3-6  U.S. Military Specifications for JP-4 Fuel .............................................................. 70

3-7  U.S. Military Specifications for JP-7 Fuel .............................................................. 71

3-8  Typical Hydrocarbon Composition of JP-4 Fuel ................................................... 72

6-1  Analytical Methods for Determining JP-4 and JP-7 in Environmental Samples ...... 99

7-1  Regulations and Guidelines Applicable to Jet Fuels .................................................. 104